Short-Term Costs in Patients with Chronic Kidney Disease Treated with Dapagliflozin: a Retrospective Cohort Study
Expert Rev Pharmacoecon Outcomes Res. 2023; online ahead of print DOI: 10.1080/14737167.2023.2237679
Analyses have found that dapagliflozin is cost-effective in the long term in patients with non-diabetic CKD and in patients with CKD with or without T2D. The slowing of eGFR decline and the early reduction in HF hospitalisation seen with dapagliflozin suggest that there is potential for short-term cost benefits in patients with CKD; however, there is a lack of real-world evidence. This retrospective observational cohort study described the impact of dapagliflozin on short-term medical costs in propensity matched patients with stage 3 CKD.
Across the overall population (n=1,566) and a subgroup of new-SGLT2i users (n=1,006), mean per-patient cardiorenal medical costs were significantly reduced by 60.8% and 49.0%, respectively, in the dapagliflozin versus non-dapagliflozin cohort (both P<0.001). Although there was an increase in mean all-cause pharmacy costs per patient in the dapagliflozin versus non-dapagliflozin cohorts (overall: $8,994 vs $6,592; P=0.01), this was offset by a reduction in all-cause medical costs (overall: $7,111 vs $11,854; P<0.001).
Keywords:
